Publications by authors named "G H Visner"

Reduced exercise capacity is common in young bilateral lung transplantation (Bi-LTx) recipients, but longer-term data on cardiac comorbidities are limited. We evaluate potential cardiac contributions to long-term exercise intolerance in this population. All Bi-LTx recipients at a single pediatric center, who completed routine clinical post-transplant cardiac assessment, including echocardiogram, cardiac exam, and cardiopulmonary exercise testing (CPET), were included.

View Article and Find Full Text PDF

Patients with congenital heart disease (CHD) resulting in significant left-to-right shunting of blood are at risk for the development of pulmonary arterial hypertension (PAH). The underlying mechanism by which pulmonary overcirculation and shear stress lead to vascular remodeling remains unclear. Our study established a new "two-hit" murine model of severe pulmonary hypertension (PH) by combining left pneumonectomy and exposure to hypoxia (LP/Hx).

View Article and Find Full Text PDF
Article Synopsis
  • - Pediatric lung transplantation for pulmonary vascular diseases has advanced significantly, with new medical therapies, surgical options, and bridging techniques like ECMO enhancing treatment possibilities.
  • - Key challenges in this area include patient adherence to post-transplant care, managing complications such as graft dysfunction and rejection, and the need for more research on rare conditions.
  • - The review article will discuss these advancements, trends, and ongoing challenges related to pediatric lung transplantation for pulmonary vascular diseases.
View Article and Find Full Text PDF

Glucagon-like peptide-1 receptor (GLP-1R) is a key regulator of glucose metabolism known to be expressed by pancreatic β cells. We herein investigated the role of GLP-1R on T lymphocytes during immune response. Our data showed that a subset of T lymphocytes expresses GLP-1R, which is upregulated during alloimmune response, similarly to PD-1.

View Article and Find Full Text PDF
Article Synopsis
  • * Strong recommendations include reducing immunosuppression as an initial management step and using the anti-CD20 monoclonal antibody (rituximab), as well as chemotherapy in specific cases.
  • * There is a lack of large randomized phase III trials for treating PTLD in pediatrics, leading to reliance on clinical experience, and the report emphasizes the need for future research on this topic.
View Article and Find Full Text PDF